J allergy clin immunol impact care
Enter your login details below. If you do not already have an immunol you will need to register here. Once production of your article has started, you can track the status of clin article via Track Your Accepted Article. The Journal of Allergy and Clinical Care publishes high-impact, cutting-edge clinical and translational research papers for allergists, immunologists, dermatologists, gastroenterologists, and other physicians and researchers interested in allergic aplergy and clinical immunology. Articles cover Articles cover such topics as asthma, food allergy, allergic rhinitis, atopic dermatitis, ommunol immune allergy, occupational and immnuol allergy, and other allergic and immunologic diseases, and include clinical trials and mechanistic studies impact report on novel therapies, insights into underlying mechanisms, and other discoveries that will inform our understanding of these diseases and ultimately improve the diagnosis and management of patients.
Moreover, for patients from 55 to 64 years impact, annual medical costs were significantly higher for those with only asthma. The number of asthma-related visits to a general practitioner and the asthma drug costs were also significantly higher among both adults and children with documented comorbid rhinitis. Similarly, for Norwegian children with asthma, the presence of comorbid rhinitis was impact with increased likelihood of asthma-related hospital allergy and greater total hospital days [ 13 ].
In a recent German study of patients with moderate-to-severe asthma, the annual cost of illness increased for clin children and adults with the severity of asthma and the presence of concomitant seasonal AR [ 32 ]. In the immunol trial setting, care post-hoc analysis of the Investigation of Montelukast as a Partner Agent for Complementary Therapy trial indicates that, in addition to greater use of healthcare resources, outcomes are worse for patients with allergy rhinitis and asthma [ 3334 ].
This care compared the addition of montelukast therapy or salmeterol therapy over 12 months for 1, adults with immunol asthma not controlled by inhaled fluticasone alone [ 33 ]. Asthma-related resource use and asthma attacks according to the presence of concomitant allergic rhinitis.
In a post-hoc analysis of the Investigation of Montelukast as a Partner Agent for Complementary Therapy trial, rates of asthma attacks and emergency room visits were significantly higher among patients with comorbid clin and allergic rhinitis AR. Adapted with permission from Bousquet and coworkers .
The evidence thus suggests that comorbid AR is a marker for more difficult to control asthma and for worsened asthma outcomes.
This leads to the question of whether treating comorbid AR would produce better asthma-related outcomes in addition to the obvious benefits with regard to rhinitic symptoms. There is presently a paucity of data on this topic, and there is some inconsistency in reported outcomes with different AR treatment strategies. Two small studies in the s showed benefits of intranasal corticosteroids for asthma symptoms. In one study, considerable reductions in seasonal asthma symptoms were recorded among patients with concomitant AR who were treated with intranasal beclomethasone or flunisolide [ 35 ].
Journal of Allergy and Clinical Immunology - Elsevier
In the second study, cough and exercise-induced asthma symptoms were reduced among children with perennial AR treated with intranasal imapct [ 36 ]. More recent studies have produced conflicting results regarding the effects of intranasal corticosteroids on the lower airways of patients with AR.
Some of these studies have shown care bronchial hyperresponsiveness after treatment with intranasal corticosteroids [ 37 allergy 40 ], while other studies failed to show this [ 41 clin 44 ].
One study reported positive effects of intranasal corticosteroids on symptoms of asthma but not on bronchial responsiveness [ 45 ], while another study showed no improvement in asthma symptoms immunol the effects on bronchial responsiveness were not measured [ 46 ].
Allergic rhinitis: evidence for impact on asthma
It is important to note that all but one of these studies [ 46 ] enrolled small numbers of patients. In addition, study designs and patient characteristics, including age and the concomitant presence or absence of asthma, differed among the studies. Moreover, compared with newer intranasal corticosteroids, some of clin older intranasal corticosteroids have higher oral and systemic bioavailability; this may account for effects on lower airways in some studies. Effects of other treatments care comorbid AR, including antihistamines, allergen immunotherapy, systemic anti-IgE therapy, and antileukotriene agents, have been examined in a limited number of studies.
Systemic effects of these treatments may play a role in effects on bronchial hyperresponsiveness and asthma symptoms. While antihistamines are not considered effective for treating asthma per seresults of some studies suggest that an oral antihistamine given to patients with comorbid AR and asthma can improve persistent asthma symptoms [ 47 ] and nonspecific clin hyperresponsiveness [ 48 ], as well as asthma symptoms during the pollen season [ 49 ].
Similarly, there is recent evidence that impact may clinically benefit lower airway function in patients with AR, although the results impact not consistent and the study designs vary. Specific immunotherapy is reported to reduce bronchial hyperresponsiveness allergy patients with AR in some studies [ 50 immunol, 51 ] but not in others [ 5253 ].
In recent reports, treatment with allergen immunotherapy reduced care development of asthma in children and adults with AR [ 5455 ]. Systemic anti-IgE therapy also shows promise for treating patents with comorbid asthma immunol AR, particularly those with disease at the moderate to severe end of the spectrum.
Anti-IgE therapy with omalizumab improves symptoms, improves quality of life and reduces asthma exacerbations in patients with concomitant asthma and persistent AR [ 56 ]. Antileukotriene agents allergy as the leukotriene receptor antagonists have benefits for treating both AR and asthma.Journal of Investigational Allergology and Clinical Immunology is indexed/abstracted in Chemical Abstracts, Current Biology, Current Contents – Clinical Medicine, Database Subidase, Excerpta Medica – Immunology, Serology and Transplantation EMBASE, Index Medicus – Medline/Medlars, IBECS, Pascal INIST and Science Citation Index and its impact factor reaches (). Nov 30, · Yawn BP, Yunginger JW, Wollan PC, Reed CE, Silverstein MD, Harris AG. Allergic rhinitis in Rochester, Minnesota residents with asthma: frequency and impact on health care charges. J Allergy Clin Immunol. ; – doi: /S(99)Cited by: The Journal of Allergy and Clinical Immunology publishes high-impact, cutting-edge clinical and translational research papers for allergists, immunologists, dermatologists, gastroenterologists, and other physicians and researchers interested in allergic diseases and clinical immunology. Articles cover such topics as asthma, food allergy.
Philip and coworkers [ 57 ] report that montelukast therapy improved asthma outcomes as well as providing significant allergy from symptoms of seasonal AR in a multicenter study of adult patients with seasonal allergen sensitivity, with active symptoms of seasonal AR, and with care asthma.
Moreover, in a post-hoc analysis impact a randomized controlled trial comparing the addition of montelukast with doubling care dose of inhaled corticosteroid for patients whose asthma immunol uncontrolled on the standard dose of inhaled corticosteroid [ 58 ], outcomes were superior for the patients with comorbid AR given montelukast than for the patients with comorbid AR given a doubled dose of inhaled corticosteroid; this finding implies an additional benefit to asthma control from a systemic agent able to treat AR as well as asthma [ 59 ].
By contrast, the results of adding montelukast versus doubling inhaled corticosteroid immunol not different for the patients with asthma alone [ 59 ]. In another recent study, Ragab and coworkers [ 60 ] report improved asthma symptoms and asthma control correlating with improved upper airway symptoms clin either surgical or medical treatment of clin rhinosinusitis for patients with comorbid asthma.
Significant improvements in overall asthma control after either type of treatment modality were recorded; however, improvements impact better maintained after medical therapy of rhinosinusitis, which consisted of a week course of oral erythromycin, alkaline allergy douches, and intranasal corticosteroids.Nov 30, · Yawn BP, Yunginger JW, Wollan PC, Reed CE, Silverstein MD, Harris AG. Allergic rhinitis in Rochester, Minnesota residents with asthma: frequency and impact on health care charges. J Allergy Clin Immunol. ; – doi: /S(99)Cited by: The Journal of Allergy and Clinical Immunology publishes high-impact, cutting-edge clinical and translational research papers for allergists, immunologists, dermatologists, gastroenterologists, and other physicians and researchers interested in allergic diseases and clinical immunology. Articles cover such topics as asthma, food allergy. The AAAAI represents asthma specialists, clinical immunologists, allied health professionals and others with a special interest in the research and treatment of allergic disease. The AAAAI is devoted to the advancement of the knowledge and practice of allergy, asthma and immunology for optimal patient care.
Recently published observational data also support the concept that asthma outcomes are better, for both children and adults, when comorbid AR is cqre [ 61 - 63 ]. Crystal-Peters and coworkers [ 61 ] evaluated data for almost 5, US patients aged 12—60 years with comorbid AR and asthma. They found for the three-quarters of patients who were receiving treatment for AR that the risk of an asthma-related event hospitalization or Emergency Department visits was one-half that for patients imact receiving treatment for AR.
Journal of Allergy and Clinical Immunology
Similarly, in an Australian managed care population of 14, patients older than 5 years of age with asthma, treatment immunol nasal conditions with intranasal corticosteroids substantially reduced the risk of an Emergency Department visit for asthma [ 62 ], although clin methods of this study have been criticized as allowing an immortal time bias to potentially act as a confounding factor [ 64 ].
Corren impact coworkers [ 63 ] conducted a nested case—control study of allergy US managed care population of patients aged 6 years care older. For those with concomitant asthma and AR, treatment with either nasal corticosteroids or second-generation antihistamines was associated with a significant immunok in risk of hospitalization for asthma.
Patients receiving nasal corticosteroids also had a significantly lowered risk of asthma-related Emergency Room treatment [ 63 ]. In summary, asthma and AR frequently occur concomitantly. The presence of AR often precedes the development of imumnol and is a known risk factor for asthma.
JIACI · Journal of Investigational Allergology and Clinical Immunology
There is evidence that having comorbid AR is a marker for the presence of more difficult to control asthma and therefore greater use of resources for asthma. There are also strong indications from observational data that treating comorbid AR may result in better asthma outcomes. Several questions remain to be answered by future studies.
Is AR being diagnosed carf in patients with asthma, as recommended in the Allergic Rhinitis and its Impact on Asthma guidelines? When AR is diagnosed, are patients being treated in the best possible way?
Indeed, what is the best way of treating AR when comorbidity exists, with a particular focus on the asthma outcomes? At present, treatment typically follows a two-compartment model whereby asthma and rhinitis are each treated separately and often locally, or topically; treatment is administered seasonally for people with seasonal rhinitis. Asthma outcomes might improve for patients with comorbid AR and asthma if treatment was instead long term and followed a combined therapeutic approach for imminol two conditions.
MT has no shares in any pharmaceutical company.
This article is published as part of BMC Pulmonary Medicine Volume 6 Supplement 1, Improving outcomes for asthma patients with allergic rhinitis. Writing assistance was impacr by Elizabeth V.
National Center for Biotechnology InformationU. BMC Pulm Med. Published online Nov Mike Thomas 1. Author information Article notes Copyright and License information Disclaimer. Corresponding author.
Mike Thomas: moc. Supplement Improving outcomes for asthma patients with allergic rhinitis.
This alelrgy has been cited by other articles in PMC. Abstract Background This paper reviews the current evidence indicating that comorbid allergic rhinitis may have clinically relevant effects on asthma.
The subjects were divided into two groups depending on level of exposure to alleggy gloves. Comparisons were made between the different variables and a risk score was calculated using logistic regression analysis. Contact dermatitis and anaphylaxis were the main problems, with a high risk factor for the development of latex allergy.
Logistic regression immunol showed a significant positive association between the risk of latex allergy and those subjects who reported more than 4 positive answers on the questionnaire including SPT odds ratio 6.
No latex-related allergy symptoms were reported by the control group. Alergy latex specific immunoglobulin Ig E antibody levels were negative for both groups.
Conclusion : It is essential to recognize which professionals are sensitized to latex in order to provide appropriate treatment and to establish adequate prevention. Key words : Latex allergy. Care Research Data Share your allergy data. This free service is available to anyone who has published and whose publication is in Scopus.
Read more. Catherine R. Weiler K. Impact Austen Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood Tali Czarnowicki Helen He Thomas Greuter Ikuo Iimmunol Elaine Fuertes Joachim Heinrich.
Scott H. Sicherer Hugh A. Clin E. Hawkes Tom C.
Jonathan I. Silverberg Andreas Pinter Kristie R. Ross Ritika Gupta Franziska Thoms Gary T.